Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126775171 | 12677517 | 1 | I | 20160816 | 20160823 | 20160823 | EXP | JP-PFIZER INC-2016391357 | PFIZER | MORITA, R.. EFFECTIVENESS OF PERIODIC INTRAVENOUS IMMUNOGLOBULIN THERAPY IN A PATIENT WITH PEMPHIGUS VULGARIS. SKIN RESEARCH. 2016;15(3):119-124 | 7.00 | DEC | F | Y | 0.00000 | 20160823 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126775171 | 12677517 | 1 | PS | METHYLPREDNISOLONE SODIUM SUCCINATE. | METHYLPREDNISOLONE SODIUM SUCCINATE | 1 | Intravenous (not otherwise specified) | 1 G, DAILY, CYCLIC FOR 3 DAYS | 11856 | 1 | G | POWDER FOR SOLUTION FOR INJECTION | |||||||
| 126775171 | 12677517 | 2 | SS | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | 24 MG, DAILY | 11153 | 24 | MG | |||||||||
| 126775171 | 12677517 | 3 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 60 MG, DAILY | 0 | 60 | MG | ||||||||
| 126775171 | 12677517 | 4 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 50 MG, DAILY | 0 | 50 | MG | ||||||||
| 126775171 | 12677517 | 5 | SS | BETAMETHASONE. | BETAMETHASONE | 1 | 5 MG, DAILY | U | 0 | 5 | MG | ||||||||
| 126775171 | 12677517 | 6 | SS | BETAMETHASONE. | BETAMETHASONE | 1 | 4.5 MG, DAILY | U | 0 | 4.5 | MG | ||||||||
| 126775171 | 12677517 | 7 | SS | BETAMETHASONE. | BETAMETHASONE | 1 | 1.5 MG, DAILY | U | 0 | 1.5 | MG | ||||||||
| 126775171 | 12677517 | 8 | C | KENKETU GLOVENIN-I | HUMAN IMMUNOGLOBULIN G | 1 | 400 MG/KG, DAILY FOR 5 DAYS | 0 | 400 | MG/KG | |||||||||
| 126775171 | 12677517 | 9 | C | CYCLOSPORINE. | CYCLOSPORINE | 1 | 100 MG, DAILY | 0 | 100 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126775171 | 12677517 | 1 | Pemphigoid |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126775171 | 12677517 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126775171 | 12677517 | Cataract | |
| 126775171 | 12677517 | Diabetes mellitus | |
| 126775171 | 12677517 | Myopathy | |
| 126775171 | 12677517 | Pancreatic neoplasm |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |